ClinicalTrials.Veeva

Menu
M

Millennium Clinical Trials | Thousand Oaks, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Secukinumab
Upadacitinib
LY3502970
SM04690
PF-06700841
Deudomperidone
Linaclotide
Ianalumab
fezolinetant
CIN-102

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 25 total trials

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose es...

Active, not recruiting
Type 2 Diabetes
T2D
Drug: Insulin Glargine
Drug: Insulin Efsitora Alfa

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Active, not recruiting
Systemic Lupus Erythematosus
Other: Placebo
Drug: Standard-of-care treatment

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (M...

Active, not recruiting
COVID-19 Infection
Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Drug: Placebo Administration

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneou...

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Ianalumab

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) f...

Enrolling
Polymyalgia Rheumatica
Drug: Secukinumab 150 mg
Other: Placebo to secukinumab

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Active, not recruiting
Rotator Cuff Tendinopathy
Drug: Secukinumab
Drug: Placebo

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

Trial sponsors

AbbVie logo
Lilly logo
Novartis logo
Amgen logo
Exact Sciences Corporation logo
Ironwood Pharmaceuticals logo
Astellas logo
B
C
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems